Repligen says HSR waiting period expires for BioLife Solutions deal
RGEN•HSR waiting period expires
Repligen says the required antitrust waiting period under the Hart-Scott-Rodino Act expired on Sept. 3, 2026, clearing a key closing condition for its planned acquisition of BioLife Solutions.
Deal terms and remaining conditions
Repligen has agreed to acquire BioLife Solutions for $11.25 in cash and 0.14 Repligen shares per BioLife share.
Completion still hinges on remaining customary conditions, including BioLife shareholder adoption at a special meeting set for Oct. 5, 2026.
